SandozSandoz strengthens US biosimilar market with CIMERLI acquisition
04 Mar 2024
Drug ApprovalAcquisition
Preview
Source: Pharmaceutical Technology
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, marking a significant expansion of its ophthalmology and biosimilar expertise in the US market.
The transaction, valued at $170m in upfront cash, encompasses the full CIMERLI business, including a biologics licence application, product inventory, specialised commercial software, ophthalmology sales and field reimbursement talent.
CIMERLI, a US Food and Drug Administration (FDA)-approved biosimilar to the reference product LUCENTIS, is indicated for the treatment of retinal diseases. These can lead to significant vision loss and are among the top ten causes of disability in the country.
The biosimilar, which is an anti–vascular endothelial growth factor therapy, has been shown to help patients with retinal diseases maintain or improve their vision.
The acquisition was agreed by the companies in January 2023.
See Also:BioCorRx files patent for treating diseases and disorders using compound 1
Preview
Source: Pharmaceutical Technology
Amylyx Pharmaceuticals files patent for treatment for neurodegenerative disease using bile acid and phenylbutyrate
Preview
Source: Pharmaceutical Technology
CIMERLI comes in 6mg/mL and 10mg/mL concentrations and is designed for injection.
It addresses retinal ailments such as diabetic macular oedema, diabetic retinopathy macular oedema after retinal vein occlusion, myopic choroidal neovascularisation, and neovascular (wet) age-related macular degeneration.
Approved by the FDA in August 2022 and launched two months later, CIMERLI met the regulator’s standards of biosimilarities, including safety, efficacy and quality.
It is the first and only FDA-approved biosimilar interchangeable with LUCENTIS for all its indications.
“With the addition of CIMERLI to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.